95 results found.

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial.
fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using IPI-145; Ofatumumab

Infinity Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO).
IPI-145; Ofatumumab

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large Clinical Trial using GS-9973

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies.
GS-9973

Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck Clinical Trial using CC-115

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
CC-115

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using IPI-145; Ofatumumab

Infinity Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07.
IPI-145; Ofatumumab

Leukemia, Lymphocytic, Chronic, B-Cell Clinical Trial using BI 836826

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia.
BI 836826

Lymphocytic Leukemia, Chronic, Lymphoma, B-Cell Clinical Trial using GDC-0853

Genentech - Recruiting 18 years or older.
- AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0853 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA.
GDC-0853

Lymphocytic Leukemia, Chronic Clinical Trial using GDC-0199 (ABT-199); Obinutuzumab

Genentech - Recruiting 18 years or older.
- A Phase Ib Multicenter Dose-Finding And Safety Study Of GDC-0199 And Obinutuzumab in Patients With Relapsed Or Refractory Or Previously Untreated Chronic Lymphocytic Leukemia.
GDC-0199 (ABT-199); Obinutuzumab

Lymphocytic Leukemia, Chronic Clinical Trial using GDC-0199 (ABT-199); rituximab [MabThera/Rituxan]; bendamustine

Genentech - Recruiting 18 years or older.
- A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of GDC-0199 (ABT-199) in Combination With Bendamustine/Rituximab (BR) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia.
GDC-0199 (ABT-199); rituximab [MabThera/Rituxan]; bendamustine

Leukemia, Lymphoma, or Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using busulfan; cyclophosphamide; Stem cell infusion; Total body irradiation

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 55 years.
- Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia.
busulfan; cyclophosphamide; Stem cell infusion; Total body irradiation

Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Clinical Trial

Cancer Centre of Monoclonal Therapy, LLC - Recruiting 18 years or older.
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors.

B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or W Clinical Trial using AVL-292

Celgene Corporation - Recruiting 18 years or older.
- Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia.
AVL-292

Chronic Lymphocytic Leukemia Clinical Trial using obinutuzumab; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Open-label, Single-arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia.
obinutuzumab; chemotherapy

Chronic Lymphocytic Leukemia Clinical Trial using GDC-0199; Rituximab [MabThera/Rituxan]; Bendamustine

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB.
GDC-0199; Rituximab [MabThera/Rituxan]; Bendamustine

Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Clinical Trial using Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

Gilead Sciences - Recruiting 18 years or older.
- A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

Leukemia Clinical Trial using Busulfan; Clofarabine; Gemcitabine; Thymoglobulin; Allogeneic Stem Cell Transplantation; Filgrastim; Tacrolimus; Methotrexate

M.D. Anderson Cancer Center - Recruiting 18 years to 70 years.
- Clofarabine, Gemcitabine and Busulfan Followed by Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL).
Busulfan; Clofarabine; Gemcitabine; Thymoglobulin; Allogeneic Stem Cell Transplantation; Filgrastim; Tacrolimus; Methotrexate

Chronic Lymphocytic Leukemia Clinical Trial using Idelalisib; Ofatumumab

Gilead Sciences - Recruiting 18 years or older.
- A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia.
Idelalisib; Ofatumumab

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using ACP-196

Acerta Pharma BV - Recruiting 18 years or older.
- A Phase 1, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia.
ACP-196

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using PCI-32765 (Ibrutinib)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study.
PCI-32765 (Ibrutinib)

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 68 years.
- Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia.
Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

Monoclonal B-Cell Lymphocytosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers..

Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), No Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Human Samples to Study Hairy Cell and Other Leukemias and to Develop Recombinant Immunotoxins for Cancer Treatment.

Small Lymphocytic Lymphoma, or CLL (Chronic Lymphocytic Leukemia) Clinical Trial using Fludarabine Phosphate; Ofatumumab; Cyclophosphamide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Fludarabine Phosphate; Ofatumumab; Cyclophosphamide

Lung or Prostatic Neoplasms, Colorectal or Kidney Neoplasms, Panc Clinical Trial using NK cells +CliniMACs CD3 and CD56 systems

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib.
NK cells +CliniMACs CD3 and CD56 systems

Non-Hodgkin Lymphoma, Multiple Myleoma, Chronic Lympocytic Leukem Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 79 years.
- A Multi-Center International Hospital-Based Case-Control Study of Lymphoma in Asia (AsiaLymph).

B-cell Chronic Lymphocytic Leukemia Clinical Trial using Lenalidomide; Placebo

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety of Lenalidomide (Revlimidr) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second Line Therapy (THE CONTINUUM TRIAL).
Lenalidomide; Placebo

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies.
yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocyt Clinical Trial using alemtuzumab; rituximab; PGG beta-glucan; flow cytometry; laboratory biomarker analysis; DNA analysis; fluorescence in situ hybridization; polymerase chain reaction; polymorphism analysis; mutation analysis

Mayo Clinic - Recruiting 18 years or older.
- Early Treatment of High Risk Chronic Lymphocytic Leukemia With Alemtuzumab, Rituximab, and PGG Beta-Glucan: A Phase I/II Trial.
alemtuzumab; rituximab; PGG beta-glucan; flow cytometry; laboratory biomarker analysis; DNA analysis; fluorescence in situ hybridization; polymerase chain reaction; polymorphism analysis; mutation analysis

Lymphocytic Leukemia, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non Interventional Study Aimed to Describe the Management of Relapse or Refractory Chronic Lymphocytic Leukemia (CLL) Patients Retreated by MabThera.

Chronic Lymphocytic Leukemia Clinical Trial using Ofatumumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Ofatumumab Early Treatment for High-Risk Treatment-Naive, Early Stage (0-II) Patients With Chronic Lymphocytic Leukemia (CLL).
Ofatumumab

Chronic Lymphocytic Leukemia Clinical Trial using Ofatumumab

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia, a Phase II Trial.
Ofatumumab

Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemi Clinical Trial using cytology specimen collection procedure

Children's Oncology Group - Recruiting N/A to 30 years.
- A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors.
cytology specimen collection procedure

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using High Dose Methylprednisolone (HDMP); Ofatumumab; Lenalidomide

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial.
High Dose Methylprednisolone (HDMP); Ofatumumab; Lenalidomide

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL, or Clinical Trial using A6

ngstrom Pharmaceuticals - Recruiting 18 years or older.
- A Phase 2 Trial to Determine the Safety, Tolerability, and Efficacy of A6, a CD44 Binding Peptide, for the Treatment of Patients With Chronic Lymphocytic Leukemia.
A6

Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymph Clinical Trial using Haploidentical Bone Marrow/Kidney

Massachusetts General Hospital - Recruiting 18 years to 70 years.
- Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Haploidentical Bone Marrow/Kidney

Lymphocytic Leukemia, Chronic Clinical Trial using rituximab [MabThera]; fludarabine; cyclophosphamide; chlorambucil

Hoffmann-La Roche - Recruiting 60 years or older.
- Prospective Randomized Study to Compare Efficacy and Safety of RFC-lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-line Therapy in Patients With B-cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status.
rituximab [MabThera]; fludarabine; cyclophosphamide; chlorambucil

Leukemia, or Chronic Lymphocytic Leukemia Clinical Trial using Lenalidomide; Fludarabine monophosphate; Melphalan; NK Infusion; CB Infusion; Tacrolimus; Mycophenolate mofetil; Rituximab

M.D. Anderson Cancer Center - Recruiting 18 years to 75 years.
- Natural Killer Cells In Allogeneic Cord Blood Transplantation.
Lenalidomide; Fludarabine monophosphate; Melphalan; NK Infusion; CB Infusion; Tacrolimus; Mycophenolate mofetil; Rituximab

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL.
ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using ipilimumab; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma.
ipilimumab; rituximab; laboratory biomarker analysis

Advanced Cancers, or Leukemia Clinical Trial using Leukapheresis; Fludarabine; Cyclophosphamide; T-cell Infusion

M.D. Anderson Cancer Center - Recruiting 18 years to 80 years.
- Autologous CD19 Specific T-cell Infusion in Patients With B-cell Chronic Lymphocytic Leukemia (B-CLL).
Leukapheresis; Fludarabine; Cyclophosphamide; T-cell Infusion

Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chr Clinical Trial using Fludarabine monophosphate; Busulfan; Stem Cell Infusion; Tacrolimus; Methotrexate; G-CSF

M.D. Anderson Cancer Center - Recruiting 5 years to 75 years.
- Randomized Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation.
Fludarabine monophosphate; Busulfan; Stem Cell Infusion; Tacrolimus; Methotrexate; G-CSF

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using alisertib; romidepsin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas.
alisertib; romidepsin; laboratory biomarker analysis

Leukemia, or Lymphoma Clinical Trial using Rituximab; Lenalidomide

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy.
Rituximab; Lenalidomide

Chronic Lymphocytic Leukemia (CLL) Clinical Trial using Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide

Hackensack University Medical Center - Recruiting 18 years or older.
- Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance.
Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide

Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission, Clinical Trial using POL6326; Leukapheresis; PBSC Transplant

Polyphor Ltd. - Recruiting 18 years to 75 years.
- A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies.
POL6326; Leukapheresis; PBSC Transplant

Chronic Lymphocytic Leukemia, or Mantle Cell Lymphoma Clinical Trial using Ublituximab; Ibrutinib

TG Therapeutics, Inc. - Recruiting 18 years or older.
- A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies.
Ublituximab; Ibrutinib

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using Ibrutinib; Bendamustine hydrochloride; Rituximab; Placebo

Janssen Research & Development, LLC - Recruiting 18 years or older.
- Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Ibrutinib; Bendamustine hydrochloride; Rituximab; Placebo

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocyti Clinical Trial using ibrutinib; rituximab; bendamustine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 65 years or older.
- A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (ò 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL).
ibrutinib; rituximab; bendamustine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, or Chronic L Clinical Trial using SAR245409

Sanofi - Recruiting 18 years or older.
- A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
SAR245409

Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chroni Clinical Trial using BMS-936564 (Anti-CXCR4)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies.
BMS-936564 (Anti-CXCR4)

Leukemia Clinical Trial using therapeutic autologous lymphocytes; cyclophosphamide

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19.
therapeutic autologous lymphocytes; cyclophosphamide

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using PCI-32765

Pharmacyclics - Recruiting 65 years or older.
- An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil).
PCI-32765

Lymphocytic Leukemia, Chronic Clinical Trial using rituximab [MabThera]; fludarabine; cyclophosphamide

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status.
rituximab [MabThera]; fludarabine; cyclophosphamide

B-cell Chronic Lymphocytic Leukemia Clinical Trial using B-CLL Vaccine; Lenalidomide

Baylor College of Medicine - Recruiting 18 years to 75 years.
- Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide.
B-CLL Vaccine; Lenalidomide

Chronic Lymphocytic Leukemia Clinical Trial using SyB L-0501

SymBio Pharmaceuticals - Recruiting 20 years to 80 years.
- A Multicenter, Open-label Phase II Study of SyB L-0501 in Patients With Chronic Lymphocytic Lymphoma.
SyB L-0501

Lymphocytic Leukemia, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- An Observational Phase IV Non Interventional Study Evaluating Further the Safety of Rituximab in Combination With Various Chemotherapies for the Treatment of Patients With CD20- Positive B-cell Chronic Lymphocytic Leukaemia in Greece.

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma, o Clinical Trial using auranofin

University of Kansas - Recruiting 18 years or older.
- A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL).
auranofin

Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasi Clinical Trial using Chemotherapy and antibodies; Miltenyi Biotec CliniMACS; Allogeneic stem cell transplantation

St. Jude Children's Research Hospital - Recruiting N/A to 24 Months.
- HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies.
Chemotherapy and antibodies; Miltenyi Biotec CliniMACS; Allogeneic stem cell transplantation

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using romidepsin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction.
romidepsin; pharmacological study

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymph Clinical Trial using bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years to 70 years.
- A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.
bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Leukemia, Leukemia, Lymphocytyc, CLL (Chronic Lymphocytic Leukemi Clinical Trial using PCI 32765

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion.
PCI 32765

B-Cell Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocyto Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Leukemia, or Lymphoma Clinical Trial using valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL.
valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

Acute Myeloid Leukemia, or Chronic Lymphocytic Leukemia Clinical Trial using SG2000

Spirogen - Recruiting 18 years to 60 years.
- An Open-Label, Phase 1/Phase 2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of the DNA Minor Groove Binding Agent SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia.
SG2000

Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Sta Clinical Trial using MOR00208; lenalidomide; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years to 80 years.
- A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)Prolymphocytic Leukemia (PLL) or Patients With Untreated CLL/SLL/PLL.
MOR00208; lenalidomide; Correlative Studies

Chronic Lymphocytic Leukemia (CLL), or Small Lymphocytic Lymphoma Clinical Trial using Idelalisib; Rituximab

Gilead Sciences - Recruiting 65 years or older.
- A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of Idelalisib Alone and in Combination With Rituximab in Elderly Subjects With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Idelalisib; Rituximab

Chronic Lymphocytic Leukemia, 17 p Deletion, or Cancer of the Blo Clinical Trial using ABT-199

AbbVie - Recruiting 18 years or older.
- A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion.
ABT-199

Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic M Clinical Trial using iTreg

Masonic Cancer Center, University of Minnesota - Recruiting 18 years to 75 years.
- Dose Escalation Study With Extension of Inducible Regulatory T Cells (iTregs) in Adult Patients Undergoing Non-Myeloablative HLA Identical Sibling Donor Peripheral Blood Stem Cell Transplantation.
iTreg

CLL, or Leukemia Clinical Trial using Eltrombopag

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia.
Eltrombopag

Leukemia Clinical Trial using cyclophosphamide; modified T cells

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab.
cyclophosphamide; modified T cells

Small Lymphocytic Lymphoma, or Chronic Lymphocytic Leukemia Clinical Trial using ABT-199; Rituximab

AbbVie - Recruiting 18 years or older.
- A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
ABT-199; Rituximab

Chronic Lymphocytic Leukemia (CLL) Clinical Trial using Autologous tumor cell extract vaccine

Xeme Biopharma Inc. - Recruiting 18 years or older.
- A Phase Ib Trial of Oncoquest-CLL Vaccine for Treatment-Naive Patients With Chronic Lymphocytic Leukemia.
Autologous tumor cell extract vaccine

Chronic Lymphocytic Leukemia (CLL), or Small Lymphocytic Lymphoma Clinical Trial using Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance

University of Wisconsin, Madison - Recruiting 18 years or older.
- HO11415: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxanr) and Lenalidomide (Revlimidr) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance

Leukemia Clinical Trial using Cyclophosphamide; Rituximab; Sapacitabine

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH.
Cyclophosphamide; Rituximab; Sapacitabine

Leukemia Lymphocytic Chronic B-Cell Clinical Trial using CC-292; Lenalidomide

Celgene Corporation - Recruiting 18 years or older.
- A Multicenter, Phase 1B, Open-Label Study to Determine the Safety and Activity of CC-292 in Combination With Lenalidomide in Subjects With Relapsed and /or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
CC-292; Lenalidomide

Lymphoma, Myeloma, or Leukemia Clinical Trial using Kappa CD28 T cells

Baylor College of Medicine - Recruiting 18 years or older.
- Phase I Study of Adoptive Transfer of Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain of Immunoglobulin Expressed in Patients With Chronic Lymphocytic Leukemia, B-Cell Lymphoma or Multiple Myeloma.
Kappa CD28 T cells

B Cell Lymphoma, or Chronic Lymphocytic Leukemia Clinical Trial using CD19CAR-28-zeta T cells; Ipilimumab

Baylor College of Medicine - Recruiting N/A or older.
- Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, Acute Lymphocytic Leukemia, and Chronic Lymphocytic Leukemia.
CD19CAR-28-zeta T cells; Ipilimumab

Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic My Clinical Trial using HSC835

Novartis - Recruiting 10 years to 55 years.
- A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies.
HSC835

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocyti Clinical Trial using alemtuzumab; ofatumumab; biopsy

Northwestern University - Recruiting 18 years or older.
- A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia.
alemtuzumab; ofatumumab; biopsy

Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodys Clinical Trial using Donor Lymphocyte Infusion; Induction Chemotherapy + DLI

Masonic Cancer Center, University of Minnesota - Recruiting 1 year to 70 years.
- Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant.
Donor Lymphocyte Infusion; Induction Chemotherapy + DLI

Leukemia Clinical Trial using rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT).
rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

Infection, or Leukemia Clinical Trial using alemtuzumab; polymerase chain reaction; flow cytometry; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Consolidation Therapy With Alemtuzumab (MabCampathr) in Patients With Chronic Lymphocytic Leukemia Who Are in Complete or Partial 2nd Remission After Cytoreduction With Fludarabine or Fludarabine Plus Cyclophosphamide or Fludarabine Plus Cyclophosphamide Plus Rituximab or Bendamustine or Bendamustine Plus Rituximab - a Phase I/II Study.
alemtuzumab; polymerase chain reaction; flow cytometry; laboratory biomarker analysis; pharmacological study

B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cance Clinical Trial using carfilzomib; Cytokine Assessment; Pharmacodynamic Studies; Proteosome Inhibition Assessment; Pharmacogenomic Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL).
carfilzomib; Cytokine Assessment; Pharmacodynamic Studies; Proteosome Inhibition Assessment; Pharmacogenomic Studies

Leukaemia, Lymphocytic, Chronic Clinical Trial using OFC Infusion; FC infusion

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia.
OFC Infusion; FC infusion

Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MD Clinical Trial using Stem Cell Transplant; Cyclophosphamide; Total Body Irradiation; Busulfan

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 55 years.
- Allogeneic Transplant for Hematological Malignancy.
Stem Cell Transplant; Cyclophosphamide; Total Body Irradiation; Busulfan

Chronic Lymphocytic Leukemia Stage A(0), Chronic Lymphocytic Leuk Clinical Trial

Gruppo Italiano Studio Linfomi - Recruiting 18 years to 80 years.
- Prospective Collection of Biological Data of Prognostic Relevance in Patients.

Leukemia, or Lymphoma Clinical Trial using anti-thymocyte globulin; rituximab; busulfan; cyclophosphamide; fludarabine phosphate; methotrexate; sirolimus; tacrolimus; laboratory biomarker analysis; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 18 years to 69 years.
- Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL).
anti-thymocyte globulin; rituximab; busulfan; cyclophosphamide; fludarabine phosphate; methotrexate; sirolimus; tacrolimus; laboratory biomarker analysis; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation

Chronic Lymphocytic Leukemia Clinical Trial using Maintenance lenalidomide

Yale University - Recruiting 18 years to 90 years.
- Maintenance Therapy With Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia.
Maintenance lenalidomide

Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopeni Clinical Trial using Eltrombopag Olamine

Fondazione Progetto Ematologia - Recruiting 18 years or older.
- Open Label Multicenter Study of Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs).
Eltrombopag Olamine

Chronic Lymphocytic Leukemia Clinical Trial using Ofatumumab

Grupo Espanol de trasplantes hematopoyeticos y terapia celular - Recruiting 18 years to 70 years.
- Ofatumumab as Part of the Reduced Intensity Conditioning Regimen for Patients With High Risk Chronic Lymphocytic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: a Pilot Study by GETH and GELLC.
Ofatumumab

Chronic Lymphocytic Leukemia Clinical Trial using ofatumumab plus dexamethasone

Brno University Hospital - Recruiting 18 years or older.
- Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia.
ofatumumab plus dexamethasone

Chronic Lymphocytic Leukemia Clinical Trial using Valproic acid

All India Institute of Medical Sciences, New Delhi - Recruiting 18 years or older.
- Use of Valproic Acid in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Valproic acid

Leukemia Clinical Trial using Immunotoxin therapy; CAT-8015 immunotoxin; Biological therapy

Cambridge Antibody Technology - Recruiting 18 years or older.
- A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia (CLL), Prolymphocytic Leukemia (PLL), or Small Lymphocytic Lymphoma (SLL).
Immunotoxin therapy; CAT-8015 immunotoxin; Biological therapy